Cationic SLN for siRNA and DNA plasmid delivery in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third leading cause of cancer-related deaths. For the treatment of HCC several drugs are under development, but the only one with proven survival benefit is sorafenib. This agent is a multikinase inhibitor that blocks Raf signaling and VEGF, PDGF and c-Kit. It has antiproliferative and antiangiogenic activity and delays tumor progression [1,2]. Moreover, systemic tumor-targeted gene delivery is attracting increasing attention as a promising alternative to conventional therapeutic strategies. At this purpose a large number of viral and non-viral vectors have been studied and applied as systems of stable transfec…

PEGYLATED PHOSPHOLIPID-POLYASPARTAMIDE COPOLYMERS AS SELF-ASSEMBLING COLLOIDAL DRUG DELIVERY SYSTEMS

LIPID AND POLYMERIC NANOSTRUCTURES FOR BRAIN DRUG DELIVERY AND TARGETING

LIPID NANOPARTICLES AS CARRIERS FOR TARGETED RELEASE OF RILUZOLE INTO THE CENTRAL NERVOUS SYSTEM

PREPARATION AND CHARACTERIZATION OF CURCUMIN-LOADED LIPID NANOPARTICLES WITH IMPROVED ANTI-CANCER THERAPEUTIC EFFICACY

NANOSTRUCTURED LIPID CARRIERS (NLC) AS DRUG DELIVERY SYSTEMS FOR SORAFENIB

ENCAPSULATION OF A MULTIKINASE INHIBITOR FOR THE TREATMENT OF HUMAN HEPATOCELLULAR CARCINOMA

Micelle polimeriche galattosilate contenenti Sorafenib: preparazione, caratterizzazione e studi di biodistribuzione